搜索
52Vol.5No.220073ChineseJournalofPharmaceuticsMar.2007p.6720060621(1981),(),,;(1965),(),,,,,,Tel.02423986321,E-mailhezhgui@mail.sy.ln.cn(2006)02006708110016:(PEG)31(PEG):R94ApolyethyleneglycolPEG20035000HOCH2(CH2OCH2)nCH2OHPEGPEGPEG200PEG300PEG400PEG600PEG2000PEG4000PEG6000PEG80001PEG200PEG300PEG400PEG6001.1PEGPEG400[1]1.2PEG200PEG600PEGPEG400PEG600PEG2002aV(PEG300):V():V()=80:5:155%2[2]6851.3PEG400PEG400Span80[3]PEG2PEG4000PEG6000PEG4000PEG4000α-[4]PEG40003PEGPEG3.1PEGPEG300PEG40002:170[5]SMZm(PEG6000):m(PEG4000):m()=57:33:10PEGPEG40015004000200001PEG525PVP0.410[3]3.2PEG100020000PEG600069[6]PEGPEGPEGPEGPEGPEGPEG12000PEG6000PEG20000PEG6000[7]3.3PEGPEG2000090%5min1h[8]PEGPEG3.4PEGCMC-NaPEG8000934[9]-PHBPEG[10]EudragitRLPEG4000PVP[11]PEG4PEG/PEGPEG3000.5%2%rhKGFPEG2004006001000BSAPEG400015%[7]W/O/WW/O/WPEGW/O/W5PEG705PEGPEGPEG40012h81%[12]PEGPEGPEGPEGPEG600030%7h[13]PEG40012h[14]6PEGpHPEG123456[1519]6.1(RES)(30min)PEGRESPEG()“”PEG(Doxil)PEG[20]PEG6.2MPSPEGMPSTween8071PEGDSPE-PEG44nmt1/2[21]Park[22]DSPE-PEGt1/2AUCMRTMPS[23]PEG6.3RESPEGPEGRESPEGRuxandraCyAPLA-PEG83℅96℅[24]PEGt1/2AUCMRT[25]6.4PEG--PEGPEG[26]1PEGPEGPEG-PEG-T2PEGPEGPEG-SSPEGPEG-SCPEGPEGPEGPEG1991PEGPEG-ADAFDA,PEGPEG-PEG-GSFPEG-α-2b4hα-2b40h168h11PEGPEGEnzon-2ChironBASFAG-TNFPharmaciaEnzon-PDGFCelltech7725Chaudhuri5PEGpH7.4TouitouPEG2601%5%5PEG400Span80PEG[3]PEGPEGPEG[27]8[28][29]9PEGPEG20PEG6PEG[30]PLA-PEG[31]PEGPEG[1],.400[J].,1996,8(3):33.[2].[M].,1991.69.[3].[J].,1995,30(12):713714.[4]PERISSUTTIB,RUBESSAF,MONEGHINIM,etal.Formulationdesignofcarbamazepinefast-releasetabletsprepared73bymeltgranulationtechnique[J].IntJPharm.2003,256(12):5363.[5],.[J].,2002,22(1):56.[6]VALLERIM,MURAP,MAESTRELLIF,etal.Developmentandevaluationofglyburidefastdissolvingtabletsusingsoliddispersiontechnique[J].DrugDevIndPharm.2004,30(5):52534.[7].[M].:,2002.440,584.[8].[M].:,1993.763.[9]OWENSTS,DANSEREAURJ,SAKRA.Developmentandevaluationofextendedreleasebioadhesivesodiumfluoridetablets[J].IntJPharm,2005,288(1):10922.[10]ZHAOJing-lian,CHENQing-yun.InosineMicrosphereUsingCompoundofPolyHydroxybutyrateandPolyEthyleneglycolasCarriertoRetardDrugReaction[J].JournalofXi’anJiaotonguniversity,2001,35(7):759.[11]GUPTASP,JAINSK.Developmentofmatrix-membranetransdermaldrugdeliverysystemforatenolol[J].DrugDeliv,2004,11(5):2816.[12]LUEu-xian,JIANGZhi-qiang,ZhangQZ,etal.Awater-insolubledrugmonolithicosmotictabletsystemutilizinggumarabicasanosmotic,suspendingandexpandingagent[J].JControlRelease,2003,92(3):37582.[13]CHENGui-liang,WANGDen-ming.Studyonsustained-releasecephalexinpellets[J].ChineseJournalofPharmaceuticals,1993,24(7):296.[14]MAKHIJASN,VAVIAPR.Controlledporosityosmoticpump-basedcontrolledreleasesystemsofpseudoephedrine.I.Celluloseacetateasasemipermeablemembrane[J].JControlRelease,2003,89(1):518.[15]BOWENS,TAREN,INOUET,etal.Relationshipbetweenmoleculemassanddurationofactivityofpolyethyleneglycolconjugatedgranulocytecolony-stimulatingfactormutein[J].ExpHematol,1999,27:425.[16]GABIZONA,MARTINF.polyethyleneglycol-coated(pegylated)liposomaldoxorubicin:rationaleforuseinsolidtumor[J].Drugs,1997,54:15.[17]HARRINGTONKJ,MOHAMMADTAGHIS,USTERPS,etal.Effectivetargetingofsolidtumorsinpatientswithlocallyadvancedcancersbyradiolabeledpegylatedliposomes[J].ClinCancerRes,2001,7:243.[18]JOHNSTONE,CRAWFORDJ,BLACKWELLS,etal.Randomized,dose-escalationstudyofSD/01comparedwithdailyfilgrastiminpatientsreceivingchemotherapy[J].JClinOncol,2000,18:2522.[19]MOLINEUXG,KINSTLERO,BRIDDELLB,etal.AnewformofFilgrastimwithsustaineddurationinvivoandenhancedabilitytomobilizePBPCinbothmiceandhumans[J].ExpHematol,1999,27:1724.[20]VAILDM,AMANTEAMA,COLBERNGT,etal.Pegylatedliposomaldoxorubicin:proofofprincipleusingpreclinicalanimalmodelsandpharmacokineticstudies[J].SeminOncol,2004,31(6Suppl13):1635.[21]LUNDBERGBB,MORTIMERBC,REDARAVETG.Submicronlipidemulsioncontainingamphipathicpolyethyleneglycolforasdrug-carrierswithprolongedcirculationtime[J].IntJPharm,1996,134(1-2):119127.[22]PARKKM,LEEMK,HWANGKJ,etal.Phospholipid-basedmicroemulsionsofflurbiprofenbythespontaneousemulsificationprocess[J].IntPharm,1999,183(2):145154.745[23]KEWen-ting,LINShyr-yi,HOHsiu-o,etal.Physicalcharacterizationsofmicroemulsionsystemsusingtocopherylpolyethyleneglycol1000succinate(TPGS)asasurfactantfortheoraldeliveryofproteindrugs[J].JControlRelease,2005,102(2):489507.[24]RUXANDRAGREF,PATRICIAQUELLEE,ALEJANDROS,etal.DevelopmentandcharacterizationofCyA-loadedpoly(lacticacid)-poly(ethyleneglycol)PEGmicro-andnanoparticles.ComparisonwithconventionalPLAparticulatecarriers.EuropeanJournalofPharmaceuticsandBiopharmaceutics[J].2000,51(2):111.[25]PALAKURTHIS,VYASSP,DIWANPV.BiodispositionofPEG-coatedlipidmicrospheresofindomethacininarthriticrats.IntJPharm,2005,290(12):5562.[26]VERONESEFM.PeptideandProteinPEGylation:areviewofproblemsandsolutions[J].Biomaterials,2001,22(5):4057.[27].[M].:,2004.214.[28].[M].:,2004.523.[29]Anonymous.TopicalPEGinburnointments.FDADrugBull,1982,12:2526.[30]HUYong-xiang,NIUJin-liang.ResearchadvancesofPEGmodifieddrugs[J].ChineseJourn